Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1

Status

Active not recruiting 11Recruiting 10Completed 7Unknown 4Withdrawn 3Terminated 3Not yet recruiting 1Approved for marketing 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

NET 3Endocrine 3Gastrointestinal 1CNS 1

Conditions

Neuroendocrine Tumors 3Pheochromocytoma 2Paraganglioma 2Pituitary Neoplasms 1Parathyroid Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoma, Medullary 1

Interventions

telotristat ethyl 3lutetium Lu 177 dotatate 33-Iodobenzylguanidine 3177Lu-octreotide, DOTA(0)-Tyr(3)- 2veliparib 1vandetanib 1gallium Ga 68 dotatate 1Tretinoin 1Temozolomide 1Isotretinoin 1Introns 1Everolimus 1Capecitabine 1177Lu-octreotate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Neuroendocrine Tumors × lutetium Lu 177 dotatate × Clear all
NCT04614766 2024-04-29

SPORE-3

University of Iowa

Phase 1/2 Withdrawn
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT03923257 2021-06-08

Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents

University of Iowa

Phase 1/2 Withdrawn
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT01860742 2016-04-05

CASTOR

Jules Bordet Institute

Phase 3 Withdrawn
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡